IMMUNE CHECKPOINT INHIBITORS IN SOLID TUMORS: MECHANISMS, CLINICAL EFFICACY, BIOMARKER-GUIDED PATIENT SELECTION, AND IMMUNE-RELATED ADVERSE EVENTS. jmsi [Internet]. 2026 Mar. 22 [cited 2026 Apr. 16];5(03):1709-14. Available from: https://ijmri.de/index.php/jmsi/article/view/6590